Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KRAS
Biotech
Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D
Merck & Co. has become the latest pharma to jump on the KRAS G12D bandwagon, paying $400 million to China’s SciBrunch for a preclinical candidate.
James Waldron
Sep 28, 2026 7:59am
GSK pens $1.3B Hutchmed deal for KRAS-EGFR cancer asset
Sep 3, 2026 7:45am
Fierce Pharma
FDA greenlights RevMed’s pancreatic cancer gamechanger
Aug 26, 2026 11:30am
BlossomHill eyes IPO to grow taller in crowded cancer fields
Jul 17, 2026 12:08pm
Roche orchestrates phase 3 lung cancer win over Amgen and BMS
Jul 2, 2026 8:30am
J&J makes $1B bet on emerging DAC space by netting Firefly Bio
Jun 8, 2026 10:05am
Fierce Pharma
Fierce Pharma
Fierce Pharma
Fierce Pharma
